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Abstract
Introduction: Valproic acid is an effective first line drug for the treatment of epilepsy. Hepatotoxicity is a rare and potentially
fatal adverse reaction for this medicine.
Objective: Firstly to characterise valproic acid reports on children with fatal outcome and secondly to determine reporting
over time of hepatotoxicity with fatal outcome.
Methods: Individual case safety reports (ICSRs) for children #17 years with valproic acid and fatal outcome were retrieved
from the WHO Global ICSR database, VigiBase, in June 2013. Reports were classified into hepatotoxic reactions or other
reactions. Shrinkage observed-to-expected ratios were used to explore the relative reporting trend over time and for patient
age. The frequency of polytherapy, i.e. reports with more than one antiepileptic medicine, was investigated.
Results: There have been 268 ICSRs with valproic acid and fatal outcome in children, reported from 25 countries since 1977.
A total of 156 fatalities were reported with hepatotoxicity, which has been continuously and disproportionally reported over
time. There were 31 fatalities with pancreatitis. Other frequently reported events were coma/encephalopathy, seizures,
respiratory disorders and coagulopathy. Hepatotoxicity was disproportionally and most commonly reported in children
aged 6 years and under (104/156 reports) but affected children of all ages. Polytherapy was significantly more frequently
reported for valproic acid with fatal outcome (58%) compared with non-fatal outcome (34%).
Conclusion: Hepatotoxicity remains a considerable problem. The risk appears to be greatest in young children (6 years and
below) but can occur at any age. Polytherapy is commonly reported and seems to be a risk factor for hepatotoxicity,
pancreatitis and other serious adverse drug reactions with valproic acid.
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Introduction
Valproic acid is a widely used antiepileptic drug (AED) that is
highly effective both in adults and children. It is one of the first line
drugs for the treatment of epilepsy. It was first used in Europe in
1968 and in the USA in 1978 [1]. The most frequent adverse drug
reactions (ADRs) of valproic acid include somnolence, weight gain,
fatigue and headache [2]. The most serious ADRs include
hepatotoxicity and pancreatitis, both of which can be fatal.
The first case reports of hepatotoxicity following the use of
valproic acid were in the late seventies [3,4]. In 1987 a
comprehensive review of 37 cases of fatal hepatotoxicity in the
USA occurring in patients receiving valproic acid between 1978
and 1984 was carried out [5]. This comprehensive review by
Dreifuss identified three major risk factors. The risk was greatest in
children under the age of three years, in patients on polytherapy
and those with signs of developmental delay [5]. A year later,
Scheffner described the deaths of 16 children in Germany [6].
Eleven of these children were on polytherapy and 11 had
developmental delay. Only two of the 16 children, however, were
under the age of three years. In 1989 Dreifuss again reviewed the
US data and described a significant reduction in mortality
associated with valproic acid in the USA and suggested that more
rational prescribing in terms of using valproic acid as monother-
apy had resulted in decreased mortality [7]. Other rare ADRs of
valproic acid that may result in death include pancreatitis [8].
In a British review of suspected ADRs and fatalities in children,
valproic acid was the AED most frequently reported with a fatality
[9]. We were therefore interested in characterising suspected
ADRs with fatal outcome for valproic acid reported worldwide
and to determine whether hepatotoxicity with fatal outcome was
still reported as a considerable problem following the guidance
suggested by Dreifuss.
Methods
The WHO Collaborating Centre for International Drug
Monitoring in Uppsala, Sweden, i.e. the Uppsala Monitoring
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Centre (UMC), receives individual case safety reports (ICSRs) of
suspected ADRs from national pharmacovigilance centres around
the world. The reports are stored in the WHO Global ICSR
database, VigiBase [10]. The database is an appropriate source to
retrieve information on rare ADRs particularly in subpopulations
such as in children because of its worldwide coverage [11]. More
than 8 million ICSRs from more than 100 countries had been
compiled in VigiBase up to June 2013.
ICSRs for children (age 1 month to 17 years) recorded with
valproic acid (suspected or interacting), according to the preferred
base in the WHO Drug Dictionary Enhanced, were extracted
from VigiBase containing data up to June 2013. Fatalities were
defined as reports with adverse reactions recorded with outcome
‘died’, or reports coded with a term indicating death (e.g. ’Sudden
death’ or ‘Death’), or with the seriousness criteria classified as
‘death’, or recorded with a post-mortem code.
Suspected duplicate reports were excluded by using an
automated screening method applied to VigiBase data and
previously described in detail [12]. A manual screening for
additional duplicates was subsequently performed. However,
duplicate reports could still remain, especially when containing
very little data. Reports specified as being sent by lawyers or
recorded as originating from published literature cases were
excluded from the analysis. Reports originating from the US are
not coded to be literature reports or not, therefore these types of
reports could still remain in the data retrieved for this study. The
restriction of using reports 1 month of age and above was applied
to reduce the number of reports relating to maternal exposure. A
manual review to remove reports with congenital anomalies
resulting from maternal exposure to valproic acid was also
performed. Reports with reactions that were most unlikely to be
the cause of death were also excluded.
Reports were grouped into being related to hepatotoxicity or
not. Several suspected ADRs can be listed on a report and when
any of the reported terms was subordinated to the Medical
Dictionary for Regulatory Activities (MedDRA) ‘Hepatic and
hepatobiliary disorders’ (High-level group term), ‘Liver function
analyses’ (High-level term), ‘Coma hepatic’, ‘Hepatic encephalop-
athy’ (Preferred terms), the report was classified as related to
hepatotoxicity. A manual review of all terms for each report was
also performed resulting in three additional reports with hyper-
ammonaemia and encephalopathy to be classified to the group of
hepatotoxic reports.
The case series considered in this study with valproic acid and
fatal outcome in the child age group were:
N All fatal reports with and without hepatotoxic events.
N Fatal reports with hepatotoxic events (as previously defined).
N Fatal reports without hepatotoxic events.
To define the timing of an event in this study, the onset date of
the event was used if completed on the report. If this was not
available the date was estimated, using firstly the suspected drug
stop date, or otherwise the date of when the national centre
received the report, or lastly the date of first VigiBase entry.
Reporting by time of the event (or estimated as described
previously) was investigated. The first time period encompassed
Figure 1. Reporting over time for valproic acid and fatalities
with hepatotoxicity; displaying the Information Component
(IC) and its 95% credibility interval, observed and expected
number of reports from VigiBase. The timing of the report is based
on the estimated onset date of the event.
doi:10.1371/journal.pone.0108970.g001
Figure 2. Reporting over time for valproic acid and fatalities
without hepatotoxicity; displaying the Information Component
(IC) and its 95% credibility interval, observed and expected
number of reports from VigiBase. The timing of the report is based
on the estimated onset date of the event.
doi:10.1371/journal.pone.0108970.g002
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the period 1977–1990 when hepatotoxicity was first recognised
and three key reviews describing risk factors of hepatotoxicity were
published [5–7]. The second time period was 1991 up to June
2013.
Relative reporting trends were graphically displayed by using
shrinkage observed-to-expected ratios on a logarithmic scale
[13,14]. The observed value consisted of the number of reports
within each case series as defined above and grouped by year of
age or time period. The expected number was computed based on
the total number of reports for valproic acid, the total number of
the event; i.e. fatalities with hepatotoxicity or fatalities without
hepatotoxicity; and the total number of reports for the children
(any drug or event), by year of age or time period. The measure is
referred to as the Information Component (IC), which is given
with its 95% credibility interval (IC025), where the lower positive
value is used to highlight disproportional reporting. The observed
and expected numbers are also included in the graphs. Non-
cumulative reporting for 5-year time periods and for each yearly
patient age is displayed.
Reports with more than one reported AED (i.e., reports listing
AEDs in addition to valproic acid) were considered cases of
polytherapy in this study. The co-reported drugs could be assigned
by the original reporter to be suspect, interacting or concomitant.
Reporting of polytherapy for the three case series with fatal
outcome were compared with corresponding groups of non-fatal
reports for valproic acid using log shrinkage odds ratios.
Ethics statement
De-identified individual case safety reports have been routinely
collected as a public health service internationally since 1968,
through the WHO Programme for International Drug Monitor-
ing. The protection of the identity of the patient and the reporter
has been routine from the outset.
Results
After exclusion of literature reports (n = 42), reports concerning
lawyers (n = 1), suspected duplicates (n = 63), maternal exposure
(n = 8) and non-fatal events (n = 5), 268 reports remained and were
analysed. Reports had been received from 25 countries worldwide
from 1977 until the end of 2012. Ages ranged from 2 months to 17
years, and 54% of the reports with a recorded patient sex
Table 1. Overall reporting of valproic acid with fatal outcome in children before and after 1990.
Year of reaction
No. reports with valproic
acid and fatal outcome
Mean No. reports with valproic
acid and fatal outcome per year
No. reports with
valproic acid
Mean No. reports with
valproic acid per year
1977–1990 101 7.2 1702 122
1991–2012 167 7.6 5058 230
1977–2012 268 7.4 6760 188
doi:10.1371/journal.pone.0108970.t001
Figure 3. Reporting by patient age in years for valproic acid and fatalities with hepatotoxicity; displaying the Information
Component (IC) and its 95% credibility interval, observed and expected number of reports from VigiBase.
doi:10.1371/journal.pone.0108970.g003
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concerned boys. In 156 reports the fatalities were recorded with
hepatotoxicity, of which hepatic failure, hepatic necrosis, abnor-
mal hepatic function and hepatocellular injury were most
frequently reported. The median number of days from start of
valproic acid to onset of reaction (time-to-onset) for the group with
hepatotoxic reactions was 66 days (IQR: 38.75–121.5) and for the
group without hepatotoxic reactions specified, the median time-to-
onset was 130 days (IQR: 54–478). The median time-to-onset is
based on reports where dates needed for the calculation had been
recorded.
The number of fatalities each year has ranged from one to 24
reports. The greatest number of reported fatalities occurred in
1983 (16 cases of hepatotoxicity and eight others). The mean
number of fatalities reported per year was 7.4 reports (Table 1)
with little change before and after 1990. Between 1977 and 1990,
68 fatalities with hepatotoxicity were reported. There were 88
fatalities reported with hepatotoxicity in the second time period
(1991–2012). However, the overall mean reporting of valproic acid
had increased from 122 per year to 230 after 1990 (Table 1).
Fatalities with hepatotoxicity have been disproportionally reported
throughout the complete time period (Figure 1). Non-hepatotoxic
fatalities have been evenly reported over time, although less
frequently than what was expected in VigiBase (Figure 2).
Hepatotoxicity was disproportionally reported for almost all
ages included in this study (Figure 3), whilst reports without
hepatotoxicity were not (Figure 4). Hepatotoxicity was most
commonly reported in children aged 6 years and under (104/
156 reports). The median ages and frequency of AED polytherapy
before and after 1990 are illustrated in Table 2. The table includes
both fatalities with hepatotoxicity and those without hepatotoxic-
ity. The relationship between polytherapy and age is shown more
completely in Table 3.
In 155 (58%) reports, one or more AEDs were reported
alongside valproic acid. A total of 28 different AEDs were reported
and the ten most frequently reported AEDs in the hepatotoxic and
non-hepatotoxic groups are listed in Table 4. Phenobarbital,
Figure 4. Reporting by patient age in years for valproic acid and fatalities without hepatotoxicity; displaying the Information
Component (IC) and its 95% credibility interval, observed and expected number of reports from VigiBase.
doi:10.1371/journal.pone.0108970.g004
Table 2. Overall reporting of valproic acid and fatal outcome reports in children with and without hepatotoxicity before and after
1990.
Type of reaction Year of reaction No. reports
Mean No. reports
per year Median age (years) IQR age (years)
Polytherapy*
No. reports (%)
Hepatotoxicity 1977–1990 68 4.9 4 2–8 45 (66)
1991–2012 88 4.0 5 2–9.25 48 (55)
Not hepatotoxicity 1977–1990 33 2.4 6 2–7 20 (61)
1991–2012 79 3.6 11 6.5–14.5 42 (53)
*Reports recorded with more than one suspected, interacting or concomitant antiepileptic medicine.
doi:10.1371/journal.pone.0108970.t002
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phenytoin and carbamazepine were the most frequently co-
reported AEDs. Polytherapy was significantly more frequently
reported for the three case series with fatalities contrasted with
corresponding non-fatal group of reports (Table 5).
Many of the cases had more than one suspected ADR listed.
Among the 268 reports, the most frequently reported events (apart
from hepatotoxicity) were coma/encephalopathy, convulsion,
pancreatitis, respiratory disorders, coagulopathy, thrombocytope-
nia and cardiac arrest/ventricular arrhythmias (Table 6). The
second largest group consisted of children who were in a coma/
encephalopathy, of which 35 of the 49 reports were co-reported
with a hepatotoxic reaction. A large group of reports involved
children who died in status epilepticus or following a seizure. It is
unlikely that these were ADRs as such, but rather that the drug
was ineffective. A number of events, not usually associated with
valproic acid were reported: metabolic acidosis, disseminated
intravascular coagulation, hyperammonaemia, apnoea, toxic
epidermal necrolysis (TEN) and aplastic anaemia. Apart from
the last two, the others seemed to be events complicating seriously
ill patients.
Discussion
Valproic acid with fatal outcome and hepatotoxicity has
continuously been reported disproportionally since 1977. Poly-
therapy was significantly more frequently reported in fatalities
than for non-fatalities and appears to remain as a considerable risk
factor for serious ADRs, including hepatotoxicity. The younger
age groups reported with hepatotoxicity had the highest proportions
of co-reported AEDs, suggesting that these ages are particularly
vulnerable to polytherapy. This is in keeping with the previous
reviews of fatal hepatotoxicity in association with valproic acid [5,6].
In the 70s, many patients with epilepsy (adults and children)
received polytherapy [15]. A prospective study in adults in the late
1970s showed that monotherapy was effective for epilepsy and also
reduced the risk of ADRs [15].
Although the greatest number of fatal cases of hepatotoxicity
occurred in children aged between 1 and 2 years (Figure 1), there
were a considerable number of cases in children of all ages,
especially in children aged six years and below. It has been
suggested that young children (less than 7.5 years) have an
increased risk of hepatotoxicity due to their abnormal metabolism
of valproic acid [16]. Clinicians need to be aware that the risk of
fatal hepatotoxicity appears to be greatest in young children (six
years and below) but that it can occur at any age. This corresponds
with two recent reviews of German fatal and non-fatal cases where
the risk of valproic acid associated hepatotoxicity was not
restricted to infants [17,18].
Unfortunately, for many reports there was insufficient informa-
tion to be certain of the full nature of the suspected ADR (coma,
convulsion and cardiac/respiratory arrest). Fatalities reported with
pancreatitis occurred in 31 reports. Pancreatitis was first reported
in 1979 and subsequently there have been several reviews and case
series [19,20]. One study, in a single hospital, identified 22
children with pancreatitis (diagnosed by using strict criteria) over a
10-year period [21]. This suggests that many cases of valproic
toxicity resulting in pancreatitis are not reported. Polytherapy was
not identified as a risk factor in any of the previous case series or
Table 3. Age groups and polytherapy* for valproic acid and fatal outcome reports, with and without hepatoxicity.
Hepatotoxicity Not hepatotoxicity
Age groups (years) No. reports Polytherapy* No. reports (%) No. reports Polytherapy* No. reports (%)
0 to 2 50 34 (68) 15 7 (47)
3 to 6 54 34 (63) 27 17 (63)
7 to 11 31 14 (45) 27 17 (63)
12 to 17 21 11 (52) 43 21 (49)
*Reports recorded with more than one suspected, interacting or concomitant antiepileptic drug.
doi:10.1371/journal.pone.0108970.t003
Table 4. The ten most frequently co-reported antiepileptic drugs with valproic acid and fatal outcome in children.*
Drug Total No. reports No. reports with hepatotoxicity No. reports without hepatotoxicity
Phenobarbital 54 44 10
Phenytoin 50 38 12
Carbamazepine 45 28 17
Clonazepam 26 17 9
Diazepam 19 7 12
Lamotrigine 11 6 5
Clobazam 7 3 4
Lorazepam 7 6 1
Topiramate 6 3 3
Levetiracetam 5 2 3
*Numbers do not add up, since more than one antiepileptic drug (AED) could be recorded on one report. AEDs could have been recorded as suspected, interacting or
concomitant medicines on the reports.
doi:10.1371/journal.pone.0108970.t004
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reviews. The majority of patients with pancreatitis in a review of
the literature, however, were receiving polytherapy [19]. In
relation to reports in VigiBase, polytherapy could be a risk factor
for pancreatitis.
Coagulopathies secondary to valproic acid are thought to occur
in up to 4% of children [22]. Thrombocytopenia is thought to
occur in between 5 and 40% of children receiving valproate
[23,24]. In the vast majority of cases, the coagulopathies are minor
and result in no clinical problems. Factors associated with
increased clinical severity of the coagulopathies are undetermined
and needs further investigation.
Both aplastic anaemia and TEN are extremely rare ADRs in
patients receiving AEDs. Aplastic anaemia has been reported in
adults receiving valproic acid [25]. It has only previously been
reported in paediatric patients in isolated case reports [23,26,27].
Similarly, Stevens-Johnson syndrome (SJS) and TEN have
predominantly been reported in adults [28] with only isolated
cases described in children on valproic acid [29]. The six cases
with SJS or TEN in our study originated from six separate
countries and were co-reported with phenobarbital (n = 2);
carbamazepine; lamotrigine plus acetazolamide; paroxetine; and
carbamazepine plus phenytoin. In an overall review of VigiBase
reports (any age and with any outcome), a disproportionally higher
reporting frequency was noted for children compared with adults
for valproic acid and aplastic anaemia. A higher number of reports
for aplastic anaemia in children with fatal outcome were also
noted (5/8 cases were children).
Table 5. Valproic acid reports with polytherapy* and fatal outcome were contrasted with non-fatal outcome reports in children,
grouped by reports with or without hepatotoxicity, or with any event.





No. reports (%) No. reports
Polytherapy*
No. reports (%) OR OR005
Hepatotoxicity 156 93 (60) 695 323 (46) 0.76 0.35
Not hepatotoxicity 112 62 (55) 5755 1892 (33) 1.32 0.81
Any event 268 155 (58) 6450 2215 (34) 1.38 1.07
*Reports recorded with more than one suspected, interacting or concomitant antiepileptic drug.
**The lower level of the 99% credibility interval for the log shrinkage odds ratio (OR005) was considered significant when above zero.
doi:10.1371/journal.pone.0108970.t005
Table 6. The most frequently reported adverse reactions for valproic acid with fatal outcome in children.






Hepatotoxicity 156 156 0 4 93 (60)
Coma states/Disturbances in consciousness/Encephalopathies 49 35 14 5 31 (63)
Seizures 42 28 14 7.5 27 (64)
Pancreatitis 31 11 20 9 16 (52)
Respiratory disorders (apnoea, respiratory depression/failure/arrest) 27 10 17 7 17 (63)
Coagulopathy/Disseminated intravascular coagulation 25 19 6 7 19 (76)
Thrombocytopenias 21 10 11 4 14 (67)
Cardiac arrest/Ventricular arrhythmias 18 5 13 11.5 8 (44)
Infections (sepsis, pneumonia) 18 10 8 8 14 (78)
Anaemias (incl. aplastic) and marrow depression 13 3 10 5 10 (77)
Renal disorders (excl nephropathies) 12 7 5 7 9 (75)
Overdose (intentional/accidental/suicide) 11 0 11 12 2 (18)
Acidosis/Metabolic acidosis/Lactic acidosis 10 6 4 6 7 (70)
Brain oedema/Increased intracranial pressure 10 6 4 7 4 (40)
Haemorrhages (incl. cerebral) 7 3 4 7 3 (43)
Gastrointestinal haemorrhages 6 4 2 8 3 (50)
Toxic epidermal necrolysis/Stevens-Johnson syndrome 6 0 6 10 5 (83)
Hyperammonaemia 4 4 0 3.5 2 (50)
Numbers do not add up, since one report can be recorded with more than one reaction.
*‘Hep’ are reports with hepatotoxicity events recorded and ‘Non-Hep’ reports are without hepatotoxicity events recorded.
**Reports recorded with more than one suspected, interacting or concomitant antiepileptic drug.
doi:10.1371/journal.pone.0108970.t006
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This study presents the reporting patterns with its caveat for
valproic acid and children with fatal outcome, see further
Appendix S1 [30]. Reports in VigiBase come from a variety of
sources and the likelihood that the reported suspected adverse
reaction is drug-related is not the same in all cases. VigiBase
reports are stored in structured format with basic information
about the patient, the drug and adverse reaction. Narratives
describing the case in more detail are rarely available electron-
ically. In this study we only used the VigiBase data available in
structured format, therefore case details to confirm a diagnosis or
to assess the likelihood of a causal relationship between a drug and
event was limited.
Several of the most commonly co-reported AEDs in this study
can in themselves be associated with liver damage. As a
consequence, there is uncertainty as to whether it was valproic
acid or the co-reported drug that induced the reaction. To reduce
this uncertainty, our report extraction generated only reports
where valproic acid had been considered the suspected drug by the
reporter.
Another limitation of the data is that co-reported AEDs may
have been omitted on the report, which could have resulted in an
underestimation of polytherapy in this study. However, we also
made an assumption that the recorded AEDs with missing
treatment dates had been used concomitantly with valproic acid
so we may have overestimated the frequency of polytherapy.
There may have been a reporting bias towards reporting more
young children with hepatotoxicity as their susceptibility to
hepatotoxicity had been reported previously [5]. The problem of
valproic acid and hepatotoxicity were introduced in the scientific
literature towards the end of 1980. This might have introduced a
bias of increased reporting around this time. The decreased
relative reporting after 1996 might therefore be an artefact
explained by unusually higher reporting before this time period.
The decreased relative reporting frequency could also reflect that
the problem is occurring less because of more careful prescribing.
We are unable to comment on the relative risk of specific ADRs
or fatalities in relation to valproic acid use because we do not have
information regarding the denominator, i.e. the number of
prescriptions for valproic acid for children with epilepsy world-
wide. Instead we used the overall reporting in VigiBase to generate
a relative frequency for our report series. Even if we could have
accessed number of the worldwide use of valproic acid in the child
population, we still would not have been able to generate a reliable
risk estimate using our data because of the known problem of
underreporting of spontaneous reports [31,32]. We know that
valproic acid is the most frequently prescribed AED for children in
several countries in Europe [33,34] and the second most
frequently prescribed AED for children in the USA, Cuba and
Egypt [35-37]. Although the number of fatalities reported is small
in relation to the number of likely prescriptions, one again needs to
recognise that the vast majority of ADRs are unreported or
unsuspected [31,32]. This, unfortunately, includes serious as well
as minor ADRs.
Risk factors for hepatotoxicity, pancreatitis and other serious
ADRs in association with valproic acid apart from polytherapy,
young age and metabolic disorders (not considered in this study)
need to be further explored. Is there for example a genetic
disposition in children and adults that make them more vulnerable
for hepatotoxicity. Until we know more, clinicians need to be
aware of the risk of rare, serious ADRs, and identify and act on
early signs of hepatotoxicity [38]. They also need to recognise that
polytherapy appears to be a major risk factor for many of the
serious ADRs in association with valproic acid.
Epilogue
As parents ourselves, we can understand that this paper might
cause concerns in parents of children, or children themselves,
using valproic acid. However, serious adverse reactions are rare,
especially those leading to fatalities, and the benefit of using an
antiepileptic medicine (to prevent seizures with their own risk)
almost certainly outweighs the risk of serious adverse reactions that
we discuss here. If you perceive unexpected changes in
your child’s health, particularly those symptoms noted
in the product information leaflet/package insert, we
encourage you to report these to your family physician.
Supporting Information
Appendix S1 Caveat document: Accompanying statement to
data released from the Uppsala Monitoring Centre, WHO
Collaborating Centre for International Drug Monitoring.
(PDF)
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